2 published verifications about Sumatriptan Sumatriptan ×
“Only two of seven triptan medicines available globally are publicly funded in New Zealand: sumatriptan and rizatriptan.”
Current New Zealand evidence supports the claim. PHARMAC’s schedule and decision records show that only sumatriptan and rizatriptan are publicly funded, while the other five triptan medicines used globally are not subsidised in New Zealand. Older sources about availability or approval do not rebut this, because they address access rather than public funding.
“In New Zealand, funded sumatriptan and funded rizatriptan are available at the standard prescription co-payment of about NZ$5 for people with a Community Services Card.”
The evidence supports that funded sumatriptan and funded rizatriptan are available in New Zealand, but it does not support the claim that people with a Community Services Card pay about NZ$5 for them. Official sources describe CSC prescription charges as reduced, and sometimes zero, relative to the usual standard charge. That makes the CSC-specific pricing in the claim inaccurately framed.